entertainment -WSS

entertainment

author：comprehensive 2025-10-01 00:57:46 - browse：6185

Exterior photo of UnitedHealth Group building — UnitedHealth Group is attempting to buy Amedisys for $3.3 billion. Courtesy UnitedHealth Group

There’s now a two-party showdown for one of the largest home health companies in the country.

UnitedHealth Group and its Optum division on Monday formally proposed to buy Amedisys for $100 per share, or about $3.3 billion.

The offer comes a few weeks after Option Care Health proposed a $3.6 billion takeover. However, Option Care’s deal is an all-stock transaction, whereas UnitedHealth would pay all cash — a potentially more attractive offer for Amedisys shareholders who want a more immediate payout that isn’t tied to the unpredictability of another company’s stock price. Option Care’s offer is technically worth closer to $2.8 billion now, due to the drop in Option Care’s stock price since the merger was announced. Amedisys is recommending shareholders vote in favor of the deal with Option Care.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Erich Jarvis studies song birds to learn about human stuttering

WSS

Stanford updates investigation of president’s past research

States increasingly look to regulate hospital facility fees

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

Why the Crimean Bridge is key to Russia's war in Ukraine

Diabetes management: Digital health tools fall short, study says

'Reaching a detente': STAT's Helen Branswell on covering Covid

explore

entertainment

Wikipedia

Jerome Adams on the need for new antivirals for Covid

Lindsay Lohan welcomes 1st child with husband Bader Shammas

In age of alternative facts, a scholarly course on calling out crap

Bring on the sabbaticals for nurses

23andMe had bad news about my health. I wish a person had delivered it

Resistance to cancer drugs: A new genetic explanation

Psychedelics group wrestles with new pharma identity

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

BioMarin wins approval for gene therapy to treat hemophilia A

Celebrate National Dole Whip Day for 3 days this week at Disney

leisure time

'Patient friction coefficient' can gauge a clinical trial's patient burden

The kidney, in all its complexity, is captured in a new atlas

Steward Health Care expansion into Malta flopped

6 surprising facts about sugar

Texas board proposes rules on abortion law emergency exemption

DOJ, FTC to increase scrutiny of all types of health care mergers

entertainment

focus

focus

entertainment